$INNV Innovus Pharma Launches its New Brand, Logo and its Latest E-Commerce-Enhanced Content Website
https://www.otcmarkets.com/stock/INNV/news/In...?id=184478
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has completed its new rebranding effort including the development and launch of its new brand, logo and website with enhanced e-commerce and content capabilities. The new website can be found at innvouspharma.com. The new website is designed to increase the e-commerce footprint of the Company and to enhance its customers’ ability to seamlessly purchase and use Innovus Pharma’s growing number of products. The website and the new branding effort for the Company has been led by its main marketing firm myEPK in New York.
“We are very happy to announce the rebranding of our Company with the introduction of our new logo and revised website with enhanced content,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “This new content will enhance our e-commerce footprint and will enable our customers to learn more about the efficacy of our products, understand the role they may play to further their health and help them to purchase such products in a relatively seamless manner. The new website features our robust Beyond Human® sales & marketing platform which transformed the Company from under $1 million in revenues in 2015 to a Company currently with multiple million dollars in revenues. This new, major rebranding effort reflects the goals of the Company to design a website and marketing and sales efforts that truly reflect the growing profitability of Innovus Pharma and its desire to become a more well known, international pharmaceutical company selling OTC drugs, devices and supplements to improve our patient’s health and lives,” he continued.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to be a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products, men’s and women’s health supplements, related diagnostics and medical devices. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC, as well as related products.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.vesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of its products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
https://www.otcmarkets.com/stock/INNV/news/In...?id=184478
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has completed its new rebranding effort including the development and launch of its new brand, logo and website with enhanced e-commerce and content capabilities. The new website can be found at innvouspharma.com. The new website is designed to increase the e-commerce footprint of the Company and to enhance its customers’ ability to seamlessly purchase and use Innovus Pharma’s growing number of products. The website and the new branding effort for the Company has been led by its main marketing firm myEPK in New York.
“We are very happy to announce the rebranding of our Company with the introduction of our new logo and revised website with enhanced content,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “This new content will enhance our e-commerce footprint and will enable our customers to learn more about the efficacy of our products, understand the role they may play to further their health and help them to purchase such products in a relatively seamless manner. The new website features our robust Beyond Human® sales & marketing platform which transformed the Company from under $1 million in revenues in 2015 to a Company currently with multiple million dollars in revenues. This new, major rebranding effort reflects the goals of the Company to design a website and marketing and sales efforts that truly reflect the growing profitability of Innovus Pharma and its desire to become a more well known, international pharmaceutical company selling OTC drugs, devices and supplements to improve our patient’s health and lives,” he continued.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to be a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products, men’s and women’s health supplements, related diagnostics and medical devices. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC, as well as related products.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.vesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of its products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
